Although for most pharmaceutical compounds the final aim is improving human health, almost all the methods used to identify and pursue therapeutic targets and to obtain new potential drugs have traditionally focused on animal models
Get full access to this article
View all access options for this article.
References
1.
EssermanL.J. & WoodcockJ. (2011). Accelerating identification and regulatory approval of investigational cancer drugs. JAMA306, 2608–2609.
2.
LiA.P. (2004). In vitro approaches to evaluate ADMET drug properties. Current Topics in Medicinal Chemistry4, 701–706.
3.
BerlinJ.A., GlasserS.C. & EllenbergS.S. (2008). Adverse event detection in drug development: Recommendations and obligations beyond phase 3. American Journal of Public Health98, 1366–1371.
4.
HartungT. (2013). Look back in anger — What clinical studies tell us about preclinical work. ALTEX30, 275–291.
5.
ArrowsmithJ. (2012). A decade of change. Nature Reviews Drug Discovery11, 17–18.
6.
EngleS.J. & PuppalaD. (2013). Integrating human pluripotent stem cells into drug development. Cell Stem Cell12, 669–677.
7.
PaulS.M., MytelkaD.S., DunwiddieC.T., PersingerC.C., MunosB.H., LindborgS.R. & SchachtA.L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery9, 203–214.
8.
BreslinS. & O'DriscollL. (2013). Three-dimensional cell culture: The missing link in drug discovery. Drug Discovery Today18, 240–249.
9.
AryaN., SardanaV., SaxenaM., RangarajanA. & KattiD.S. (2012). Recapitulating tumour microenvironment in chitosan–gelatin three-dimensional scaffolds: An improved in vitro tumour model. Journal of the Royal Society, Interface9, 3288–3302.
10.
KnightA. (2007). Animal experiments scrutinised: Systematic reviews demonstrate poor human clinical and toxicological utility. ALTEX24, 320–325.
11.
van VlietE. (2011). Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century. ALTEX28, 17–44.
12.
MestasJ. & HughesC.C. (2004). Of mice and not men: Differences between mouse and human immunology. Journal of Immunology172, 2731–2738.
13.
BradyC.A. (2008). Of mice and men: The potential of high-resolution human immune cell assays to aid the pre-clinical to clinical transition of drug development projects. Drug Discovery World, Winter 2008/09. London, UK: RJ Communications & Media Ltd. Available at: http://ddw.net-genie.co.uk/enabling_technologies/261930/of_mice_and_men.html (Accessed 31.08.14).
14.
Mouse Genome Sequencing Consortium (2002). Initial sequencing and comparative analysis of the mouse genome. Nature, London420, 520–562.
15.
NelsonD.R., KoymansL., KamatakiT., StegemanJ.J., FeyereisenR., WaxmanD.J., WatermanM.R., GotohO., CoonM.J., EstabrookR.W., GunsalusI.C. & NebertD.W. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics6, 1–42.
16.
LindbergL.P. & NegishiM. (1989). Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature, London339, 632–634.
17.
SchnabelJ. (2008). Neuroscience: Standard model. Nature, London454, 682–685.
18.
Gordon, P.H., Moore, D.H., Miller, R.G., Florence, J.M., Verheijde, J.L., Doorish, C., Hilton, J.F., Spitalny, G.M., MacArthur, R.B., Mitsumoto, H., Neville, H.E., Boylan, K., Mozaffar, T., Belsh, J.M., Ravits, J., Bedlack, R.S., Graves, M.C., McCluskey, L.F., Barohn, R.J., Tandan, R.; Western ALS Study Group (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurology6, 1045–1053.
19.
Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., Aisen, P.S.; Alzheimer's Disease Cooperative Study Steering Committee, Siemers, E., Sethuraman, G., Mohs, R.; Semagacestat Study Group (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine369, 341–350.
PerelP., RobertsI., SenaE., WhebleP., BriscoeC., SandercockP., MacleodM., MigniniL.E., JayaramP. & KhanK.S. (2007). Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ334, 197.
22.
PoundP., EbrahimS., SandercockP., BrackenM.B., RobertsI.; Reviewing Animal Trials Systematically (RATS) Group (2004). Where is the evidence that animal research benefits humans?BMJ328, 514–517.
23.
GreekR. & HansenL. (2013). Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse. Progress in Biophysics & Molecular Biology113, 231–253.
24.
SeymourM. (2009). The best model for humans is human — How to accelerate early drug development safely. ATLA37, Suppl. 1, 61–65.
25.
LinJ.F. & LuA.Y.H. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacological Reviews49, 403–449.
26.
SutherlandM.L., FabreK.M. & TagleD.A. (2013). The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Research & Therapy4, Suppl. 1, I1.
27.
SeokJ., WarrenH.S., CuencaA.G., MindrinosM.N., BakerH.V., XuW., RichardsD.R., McDonald-SmithG.P., GaoH., HennessyL., FinnertyC.C., LópezC.M., HonariS., MooreE.E., MineiJ.P., CuschieriJ., BankeyP.E., JohnsonJ.L., SperryJ., NathensA.B., BilliarT.R., WestM.A., JeschkeM.G., KleinM.B., GamelliR.L., GibranN.S., BrownsteinB.H., Miller-GrazianoC., CalvanoS.E., MasonP.H., CobbJ.P., RahmeL.G., LowryS.F., MaierR.V., MoldawerL.L., HerndonD.N., DavisR.W., XiaoW., TompkinsR.G.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the USA110, 3507–3512.
28.
SenaE., WhebleP., SandercockP. & MacleodM. (2007). Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke38, 388–394.
29.
van der WorpH.B., HowellsD.W., SenaE.S., PorrittM.J., RewellS., O'CollinsV. & MacleodM.R. (2010). Can animal models of disease reliably inform human studies? PLoS Medicine7, e1000245.
30.
BaileyJ. & TaylorK. (2009). The SCHER report on non-human primate research — Biased and deeply flawed. ATLA37, 427–435.
31.
GreekR. & MenacheA. (2013). Systematic reviews of animal models: Methodology versus epistemology. International Journal of Medical Sciences10, 206–221.
32.
KolaI. & LandisJ. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery3, 711–715.
33.
MakI.W., EvaniewN. & GhertM. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research6, 114–118.
34.
EnnaS.J. & WilliamsM. (2009). Defining the role of pharmacology in the emerging world of translational research. Advances in Pharmacology57, 1–30.
35.
LazicS.E. & EssiouxL. (2013). Improving basic and translational science by accounting for litter-to-litter variation in animal models. BMC Neuroscience14, 37.
36.
LeistM. & HartungT. (2013). Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. Archives of Toxicology87, 563–567.
37.
AggarwalB.B., DandaD., GuptaS. & GehlotP. (2009). Models for prevention and treatment of cancer: Problems vs promises. Biochemical Pharmacology78, 1083–1094.
38.
ColemanR.A. (2011). Human tissue in the evaluation of safety and efficacy of new medicines: A viable alternative to animal models? ISRN Pharmaceutics2011, 806789.
39.
LiA.P. (2014). Biomarkers and human hepatocytes. Biomarkers in Medicine8, 173–183.
StinglL., VölkelM. & LindlT. (2009). 20 years of hypertension research using genetically modified animals: No clinically promising approaches in sight. ALTEX26, 41–51.
42.
BhogalN. & CombesR. (2006). The relevance of genetically altered mouse models of human disease. ATLA34, 429–454.
MertensJ., StüberK., WunderlichP., LadewigJ., KesavanJ.C., VandenbergheR., VandenbulckeM., van DammeP., WalterJ., BrüstleO. & KochP. (2013). APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-sec-retase modulation. Stem Cell Reports1, 491–498.
45.
RiceJ. (2012). Animal models: Not close enough. Nature, London484, S9.
46.
FrieseM.A., MontalbanX., WillcoxN., BellJ.I., MartinR. & FuggerL. (2006). The value of animal models for drug development in multiple sclerosis. Brain129, 1940–1952.
47.
BealM.F. (2010). Parkinson's disease: A model dilemma. Nature, London466, S8–S10.
AkabaneT., TabataK., KadonoK., SakudaS., TerashitaS. & TeramuraT. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metabolism & Disposition38, 308–316.
50.
CaoX., GibbsS.T., FangL., MillerH.A., LandowskiC.P., ShinH.C., LennernasH., ZhongY., AmidonG.L., YuL.X. & SunD. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharmaceutical Research23, 1675–1686.
51.
ChiouW.L., JeongH.Y., ChungS.M. & WuT.C. (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharmaceutical Research17, 135–140.
52.
BaileyJ., KnightA. & BalcombeJ. (2005). The future of teratology research is in vitro. Biogenic Amines19, 97–145.
BasketterD.A., ClewellH., KimberI., RossiA., BlaauboerB., BurrierR., DaneshianM., EskesC., GoldbergA., HasiwaN., HoffmannS., JaworskaJ., KnudsenT.B., LandsiedelR., LeistM., LockeP., MaxwellG., McKimJ., McVeyE.A., OuédraogoG., PatlewiczG., PelkonenO., RoggenE., RovidaC., RuhdelI., SchwarzM., SchepkyA., SchoetersG., SkinnerN., TrentzK., TurnerM., VanparysP., YagerJ., ZurloJ. & HartungT. (2012). A roadmap for the development of alternative (non-animal) methods for carcinogenicity testing. ALTEX29, 41–55.
55.
van MeerP.J., KooijmanM., BrinksV., Gispen-de WiedC.C., Silva-LimaB., MoorsE.H. & SchellekensH. (2013). Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs5, 810–816.
56.
BaileyJ., ThewM. & BallsM. (2013). An analysis of the use of dogs in predicting human toxicology and drug safety. ATLA41, 335–350.
57.
BaileyJ., ThewM. & BallsM. (2014). An analysis of the use of animal models in predicting human toxicology and drug safety. ATLA42, 181–199.
58.
WangS.J., HungH.M. & O'NeillR. (2011). Adaptive design clinical trials and trial logistics models in CNS drug development. European Neuropsychopharmacology21, 159–166.
59.
JangK.J., MehrA.P., HamiltonG.A., McPartlinL.A., ChungS., SuhK.Y. & IngberD.E. (2013). Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integrative Biology (Cambridge) 5, 1119–1129.
60.
GiriS., BraumannU.D., GiriP., AcikgözA., ScheibeP., NieberK. & BaderA. (2013). Nano-structured self-assembling peptides as a defined extracellular matrix for long-term functional maintenance of primary hepatocytes in a bioartificial liver modular device. International Journal of Nano-medicine8, 1525–1539.
61.
EkwallB. (1999). Overview of the final MEIC results: II. The in vitro–in vivo evaluation, including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans. Toxicology in Vitro13, 665–673.
62.
MuellerD., KrämerL., HoffmannE., KleinS. & NoorF. (2014). 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicology in Vitro28, 104–112.
63.
KrugA.K., KoldeR., GasparJ.A., RempelE., BalmerN.V., MeganathanK., VojnitsK., BaquiéM., WaldmannT., Ensenat-WaserR., JagtapS., EvansR.M., JulienS., PetersonH., ZagouraD., KadereitS., GerhardD., SotiriadouI., HekeM., NatarajanK., HenryM., WinklerJ., MarchanR., StoppiniL., BosgraS., WesterhoutJ., VerweiM., ViloJ., KortenkampA., HeschelerJ., HothornL., BremerS., van ThrielC., KrauseK.H., HengstlerJ.G., RahnenführerJ., LeistM. & SachinidisA. (2013). Human embryonic stem cell-derived test systems for developmental neurotoxicity: A transcriptomics approach. Archives of Toxicology87, 123–143.
64.
HengstlerJ.A., LeistM. & HeschelerJ. (2013). Briefing paper: The Novel FP7 ESNATS Test Systems of Developmental Toxicity: State-of-the art and Future Perspectives, 8 pp. Paris, France: ARTTIC Project Office. Available at: http://www.esnats.eu/uploads/images/ESNATS_Briefing_paper_13-09-2013.pdf (Accessed 31.08.14).
65.
HuhD., LeslieD.C., MatthewsB.D., FraserJ.P., JurekS., HamiltonG.A., ThorneloeK.S., McAlexanderM.A. & IngberD.E. (2012). A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Science Translational Medicine4, 159ra147.
66.
KimH.J. & IngberD.E. (2013). Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integrative Biology (Cambridge) 5, 1130–1140.
67.
MoraesC., MehtaG., Lesher-PerezS.C. & TakayamaS. (2011). Organs-on-a-chip: A focus on compartmentalized microdevices. Annals of Biomedical Engineering40, 1211–1227.
HuhD., HamiltonG.A. & IngberD.E. (2011). From 3D cell culture to organs-on-chips. Trends in Cell Biology21, 745–754.
70.
MarxU., WallesH., HoffmannS., LindnerG., HorlandR., SonntagF., KlotzbachU., SakharovD., TonevitskyA. & LausterR. (2012). ‘Human-on-a-chip’ developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man?ATLA40, 235–257.
71.
MandeniusC.F., AnderssonT.B., AlvesP.M., Batzl-HartmannC., BjörquistP., CarrondoM.J., ChesneC., CoeckeS., EdsbaggeJ., FredrikssonJ.M., GerlachJ.C., HeinzleE., Ingelman-SundbergM., JohanssonI., Küppers-MuntherB., Müller-VieiraU., NoorF. & ZeilingerK. (2011). Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines — A report on the Vitrocellomics EU-project. ATLA39, 147–171.
72.
CaoL., TanL., JiangT., ZhuX.C. & YuJ.T. (2014). Induced pluripotent stem cells for disease modeling and drug discovery in neurodegenerative diseases. Molecular Neurobiology, E-pub ahead of print [doi: 10.1007/s12035-014-8867-6].
